The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Inception Date: 01/05/2006
Primary Benchmark: DJ US Select Pharms TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.44%
Management Expense Ratio: 0.44 %
|JNJ||Johnson & Johnson||9.79 %|
|PFE||Pfizer Inc.||8.75 %|
|MRK||Merck & Company Inc. (new)||7.50 %|
|BMY||Bristol-Myers Squibb Company||7.04 %|
|LLY||Eli Lilly and Company||5.46 %|
|ZTS||Zoetis Inc. Class A||4.99 %|
|AGN||Allergan plc||4.80 %|
|MYL||Mylan N.V.||3.89 %|
|PRGO||Perrigo Company plc||2.82 %|
|JAZZ||Jazz Pharmaceuticals plc||2.76 %|
|XLV||SPDR Select Sector Fund - Heal..||0.14 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IYH||iShares U.S. Healthcare||0.44 %||
|IHI||iShares U.S. Medical Devices||0.44 %||
|IXJ||iShares Global Healthcare||0.48 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||18.49%||43%||F||40%||F|
|Risk Adjusted Return||62.96%||43%||F||55%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.